ITI Life Sciences Seeks to Fund Innovative Drug Discovery Programme based on Ubiquitin


Following the publication of its comprehensive foresighting report on Emerging Drug Targets, ITI Life Sciences issues a Call for Expressions of Interest from organisations or individuals with expertise in the field of ubiquitin Signalling. ITI Life Sciences has identified this area as having significant potential and seeks to fund research and development opportunities, which will form part of an innovative drug discovery programme. Responses are invited from companies, agencies, institutes, academia and individuals. No geographical restrictions apply and ITI Life Sciences welcomes responses to this call from non-UK organisations. ITI Life Sciences is committed to helping its partners achieve success and ensuring the successful onward commercialisation of programme outputs. The Ubiquitin Proteasome System (UPS) was discovered in 1980 and implicated in key protein degradation mechanisms via a small protein named Ubiquitin. A resultant Nobel prize in 2004 coincided in links with Ubiquitin to a range of additional key cellular functions and diseases including cancer, neurodegenerative, metabolic, inflammatory and infectious diseases. Detailed analysis by ITI Life Sciences of the scientific and commercial landscape has reinforced its belief that the UPS provides a rich source of emerging drug targets, yet it remains a relatively unexploited and largely uncharted area for drug discovery. ITI Life Sciences also believes that the generation of novel tools and reagents will play a pivotal role in promoting new breakthroughs in this area.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances